At Washington Health Institute in Washington, D.C., we believe that the best defense against HIV is prevention. We are pleased to offer Apretude Injectable PrEP (pre-exposure prophylaxis), an FDA-approved series of injections that reduces patients’ risk of contracting HIV. According to the FDA, patients that underwent Apretude injectable PrEP treatment were 69% less likely to contract HIV compared to patients who took oral HIV prevention medications.
Why Choose Apretude Injectable PrEP?
Over 1.2 million people in the United States have HIV, according to the U.S. Department of Health & Human Services, and the disease disproportionally affects racial, ethnic and sexual minority groups. While there is, unfortunately, no definitive cure for HIV, Apretude Injectable PrEP can reduce patients’ risk of contracting HIV in the first place. While other PrEP methods require patients to take a daily pill, Apretude Injectable PrEP consists of an injection every other month, allowing patients to be easily and efficiently protected from HIV.